Squamous Cell Carcinoma of the Head and Neck
Welcome,         Profile    Billing    Logout  
 149 Companies   206 Products   206 Products   68 Mechanisms of Action   6 Trials   1509 News 


12345678910111213...3132»
  • ||||||||||  samalizumab (ALXN 6000) / The Leukemia & Lymphoma Society, AstraZeneca
    Trial termination:  Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM (clinicaltrials.gov) -  Mar 5, 2019   
    P1/2,  N=26, Terminated, 
    Phase classification: P4 --> P=N/A Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
    Enrollment change, Trial termination:  Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) -  Feb 26, 2019   
    P2,  N=20, Terminated, 
    Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns. N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections.
  • ||||||||||  Javlor (vinflunine) / Pierre Fabre
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer (clinicaltrials.gov) -  Feb 4, 2019   
    P3,  N=459, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Sep 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Oct 2017
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial completion, Metastases:  ICRAT: InductionChemo-Radio-Antibody-Treatment (clinicaltrials.gov) -  Jan 31, 2019   
    P2,  N=94, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Oct 2017 Recruiting --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial completion, Trial completion date, Metastases:  Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. (clinicaltrials.gov) -  Jan 18, 2019   
    P3,  N=370, Completed, 
    Active, not recruiting-> Completed | N=42 --> 26 Active, not recruiting --> Completed | Trial completion date: May 2019 --> Nov 2018
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Biomarker, Trial completion, Trial completion date, Trial primary completion date, Metastases:  ERBITUX (clinicaltrials.gov) -  Jan 3, 2019   
    P2,  N=40, Completed, 
    Phase classification: P1/2 --> P1 Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Feb 2017 | Trial primary completion date: Sep 2017 --> Nov 2015
  • ||||||||||  ficlatuzumab (AV-299) / LG Chem
    Biomarker, Phase classification, Enrollment change, Trial termination, Trial primary completion date, Metastases:  Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Jan 3, 2019   
    P1b,  N=1, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Feb 2017 | Trial primary completion date: Sep 2017 --> Nov 2015 Phase classification: P1 --> P1b | N=24 --> 1 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Sep 2016; the investigator left the institution
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment change, Trial withdrawal:  Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma (clinicaltrials.gov) -  Nov 26, 2018   
    P2,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=30 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
    Enrollment closed, Enrollment change, Trial primary completion date:  Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) -  Sep 19, 2018   
    P1,  N=42, Active, not recruiting, 
    Completed --> Terminated Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, alisertib (MLN8237) / Puma
    Trial completion, Combination therapy, Metastases:  MLN8237 in Head and Neck Cancer (clinicaltrials.gov) -  Aug 29, 2018   
    P1,  N=9, Completed, 
    Active, not recruiting --> Completed | N=92 --> 142 Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date:  ROSAM: Role of SAMITAL (clinicaltrials.gov) -  Jul 20, 2018   
    P2,  N=120, Completed, 
    Completed --> Terminated; Slow accrual and high levels of toxicity lead to early termination. Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018
  • ||||||||||  oxaliplatin / Generic mfg.
    Enrollment change, Trial termination:  Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer (clinicaltrials.gov) -  May 1, 2018   
    P2,  N=6, Terminated, 
    Active,not recruiting --> Completed | N=42 --> 26 N=20 --> 6 | Active, not recruiting --> Terminated; Halted prematurely due to slow accrual
  • ||||||||||  Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
    Trial completion, Combination therapy:  Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) -  Apr 11, 2018   
    P1,  N=32, Completed, 
    Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed
  • ||||||||||  Rituxan (rituximab) / Roche
    Trial completion, Enrollment change:  BR in Patients With CLL With Comorbidities and/or Renal Dysfunction (clinicaltrials.gov) -  Mar 31, 2018   
    P1,  N=8, Completed, 
    Trial completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | N=49 --> 8